As an optometrist it is my goal to diagnose macular degeneration early and stop its progression so that my patients never need to lose vision or have eye injections. I also want to help people who have lost vision to regain as much as possible and make eye injections more effective and less necessary. This is possible with the Macular Program.
The reason why the current standard of care fails to stop the progression of macular degeneration is because it is a simplistic one-size-fits-all strategy that does little to help the cells in the macula. As a result, many people lose vision, and need eye injections.
THE METHOD
While AREDS, the current standard of care, focuses on slowing disease progression with antioxidant vitamins and minerals, it does not reverse damage or target multiple underlying biochemical processes driving macular degeneration. The Macular Program fills this gap with a more comprehensive, science-backed approach that has helped patients stabilize, improve, and even reclaim lost vision.
The Macular Program goes beyond the current standard of care by addressing multiple causes of macular degeneration guided by comprehensive blood work that is carefully interpreted in the context of the medical history. Thankfully, the results show that it is possible to stabilize and in some cases reverse vision loss from macular degeneration and help reduce the need for eye injections.
What This Means
It is crucial to realize that the sooner treatment is implemented the better will be the visual outcome. Don’t wait until vision loss occurs and becomes irreversible. It is far easier to stabilize vision than it is to reverse vision loss. Schedule a call with the Macular Program to learn how it can benefit your eyesight and general health.
Unlike AREDS, which primarily slows progression, the Macular Program has shown success in stabilizing and even improving vision for both dry and wet macular degeneration.
For patients with wet macular degeneration, the program works to reduce VEGF expression, often lowering the frequency of injections needed.
AREDS provides a one-size-fits-all supplement formula, while the Macular Program creates tailored plans based on comprehensive lab work, addressing oxidative stress, inflammation, and hormonal imbalances unique to each patient.
Beyond antioxidant support, the Macular Program focuses on promoting favorable gene expression (epigenetics) and enhancing overall cellular health—something AREDS does not address.
May slow the progression of intermediate to advanced AMD
Provides antioxidant and mineral support
One-size-fits-all formula
No effect on injections
Epigenetics not addressed
Supports eye health with antioxidants
Limited to eye health
Based on slowing AMD progression in specific cases
Prevent, stabilize, and potentially reverse vision loss for both dry and wet AMD
Addresses root causes: oxidative stress, inflammation, hormonal imbalances, and epigenetics
Tailored plans based on individual lab results and health profiles
Clinically shown to stabilize and even improve vision
Reduces dependence on eye injections for wet AMD
Includes custom interventions like targeted antioxidants, hormone balancing, and cellular regeneration support.
Activates protective genes and deactivates harmful ones (e.g., VEGF for wet AMD)
Improves overall cellular health and metabolic function
Documented success in stabilizing and improving vision across a broader range of patients
Personalized care plans based on your unique medical history and lab results.
Advanced diagnostics like Altris.ai for superior OCT evaluations.
Full support through training, brochures, and patient engagement tools.
20% co-management revenue opportunities and supplement sales potential.
Follow Us
© Copyright 2025. Company Name. All rights reserved.